UW Medicine reports new mRNA flu vaccine shows about 30% higher efficacy for adults over 50
A newly approved mRNA influenza vaccine for people aged 50 and older is reported to be roughly 30% more effective than traditional flu shots, according to UW Medicine.
UW Medicine said the mRNA-based influenza vaccine, marketed as mFLUSIVA, offers about a 30% increase in effectiveness for adults 50 and older compared with standard flu vaccines. The vaccine, which uses the same technology as COVID-19 shots, is designed to generate antibodies that recognize a broader range of influenza strains and provide longer-lasting protection.
Dr. Deborah Fuller of UW Medicine explained that immune function declines with age, a process known as immunosenescence, making older adults less responsive to conventional vaccines. She advised individuals in the target age group to consult their doctor or pharmacist before receiving the new shot, especially if they experienced severe reactions to previous mRNA COVID-19 vaccines.
The vaccine is being distributed to major pharmacy chains such as CVS and Walgreens, though availability may vary by location. Medicare is expected to cover the shot for adults 65 and older, while coverage for those aged 50-64 remains uncertain.
State health data show that 29.2% of eligible Washington residents received a flu vaccine last season, and flu-related deaths in the state have risen, with over 90% of recent fatalities occurring in people 50 and older. Clinical trials indicated that the mRNA vaccine can cause more pronounced side effects, including fatigue and muscle or joint aches, than the traditional flu shot.